Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

18
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
18
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

20
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
20
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Neural Regulation01:37

Neural Regulation

34.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-specific differences and diagnostic tool performance in the neuropsychiatric profile of Parkinson's disease.

BMC neurology·2026
Same author

Taiwan Clinical Practice Guidelines for Myasthenia Gravis.

Acta neurologica Taiwanica·2026
Same author

Neuroprotective Effects of Glucosamine in Huntington's Disease Through NLRP3 Inflammasome Inhibition.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology·2025
Same author

Epidemiology and diagnostic challenges in neuromyelitis optica spectrum disorder in Taiwan: a hospital-based surveillance accompanied by a nationwide study.

Brain communications·2025
Same author

Alteration of bile acid profile in patients with neuromyelitis optica spectrum disorders and multiple sclerosis.

Multiple sclerosis and related disorders·2025
Same author

The potential of mulberry (Morus alba L.) leaf extract against pro-aggregant tau-mediated inflammation and mitochondrial dysfunction.

Neurochemistry international·2025

Related Experiment Video

Updated: Apr 26, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

16.2K

FBXO7 Y52C polymorphism as a potential protective factor in Parkinson's disease.

Chiung-Mei Chen1, I-Cheng Chen1, Yi-Cheng Huang2

  • 1Department of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan.

Plos One
|July 17, 2014
PubMed
Summary

The F-box only protein 7 (FBXO7) gene Y52C variant may reduce Parkinson's disease risk in Chinese populations. This variant affects protein stability and neuronal growth, suggesting a protective role against Parkinson's disease.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

6.9K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

36.1K

Related Experiment Videos

Last Updated: Apr 26, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

16.2K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

6.9K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

36.1K

Area of Science:

  • Genetics and Molecular Biology
  • Neurodegenerative Diseases
  • Biochemistry

Background:

  • Mutations in the F-box only protein 7 (FBXO7) gene are linked to Parkinson's disease (PD)-15 (PARK15).
  • Identifying novel variants and understanding their functional impact is crucial for Parkinson's disease research.

Purpose of the Study:

  • To identify new variants in the FBXO7 gene in Taiwanese early-onset Parkinson's disease patients.
  • To assess the association of known FBXO7 variants (Y52C and M115I) with Parkinson's disease risk.
  • To investigate the functional consequences of the Y52C variant on FBXO7 protein stability, TRAF2 interaction, and neuronal differentiation.

Main Methods:

  • Sequencing of FBXO7 cDNA in 80 Taiwanese early-onset Parkinson's disease patients.
  • Case-control study to assess the association of Y52C and M115I variants with Parkinson's disease risk.
  • In vitro expression studies of wild-type and mutant FBXO7, including protein decay assays, interaction studies with TRAF2, and ubiquitination assays.
  • In silico modeling of the Y52C variant.
  • Neuronal differentiation assays in SH-SY5Y cells.

Main Results:

  • Two known FBXO7 variants, Y52C and M115I, were identified in Taiwanese early-onset Parkinson's disease patients.
  • A significant association was found between the Y52C G allele and decreased Parkinson's disease risk when combining Taiwanese and Chinese cohorts.
  • The Cys52 FBXO7 variant exhibited reduced protein decay, enhanced interaction with TRAF2, promoted TRAF2 ubiquitination, and led to increased neuronal outgrowth in vitro.
  • In silico modeling suggested increased stability for the Cys52 variant.

Conclusions:

  • The Cys52 variant of FBXO7 may confer reduced susceptibility to Parkinson's disease in the Chinese population.
  • FBXO7's role in protein stability, TRAF2 regulation, and neuronal development is implicated in Parkinson's disease pathogenesis.
  • Further research is warranted to elucidate the precise mechanisms by which FBXO7 variants influence Parkinson's disease risk.